Lexeo Therapeutics (LXEO) Depreciation & Amortization (CF) (2022 - 2026)

Lexeo Therapeutics has reported Depreciation & Amortization (CF) for 5 years, with the latest figure at $73000.0 in Q1 2026.

• Quarterly Depreciation & Amortization (CF) rose 21.67% year-over-year to $73000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $281000.0 (down 4.75% YoY) and the FY2025 annual result came in at $268000.0, down 11.84% from the prior year.
• Depreciation & Amortization (CF) steadied at $73000.0 in Q1 2026 per LXEO's latest filing, from $73000.0 in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $83000.0 in Q3 2024 and troughed at $57000.0 in Q1 2023.
• A 5-year average of $69571.4 and a median of $73000.0 in 2025 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2023 and 2025: Depreciation & Amortization (CF) surged 32.76% in 2023, then dropped 19.48% in 2025.
• Over 5 years, Depreciation & Amortization (CF) stood at $58000.0 in 2022, then surged by 32.76% to $77000.0 in 2023, then slipped by 2.6% to $75000.0 in 2024, then fell by 2.67% to $73000.0 in 2025, then changed by 0.0% to $73000.0 in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $73000.0, $73000.0, and $73000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.